News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
719,793 Results
Type
Article (42545)
Company Profile (295)
Press Release (676953)
Multimedia
Podcasts (81)
Webinars (12)
Section
Business (210474)
Career Advice (2092)
Deals (36634)
Drug Delivery (107)
Drug Development (83066)
Employer Resources (175)
FDA (16586)
Job Trends (15417)
News (356114)
Policy (33933)
Tag
Academia (2598)
Accelerated approval (5)
Adcomms (21)
Allergies (92)
Alliances (51450)
ALS (99)
Alzheimer's disease (1403)
Antibody-drug conjugate (ADC) (140)
Approvals (16583)
Artificial intelligence (280)
Autoimmune disease (24)
Automation (17)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (112)
Biotechnology (189)
Bladder cancer (79)
Brain cancer (29)
Breast cancer (295)
Cancer (2360)
Cardiovascular disease (188)
Career advice (1753)
Career pathing (31)
CAR-T (157)
Cell therapy (444)
Cervical cancer (20)
Clinical research (67649)
Collaboration (882)
Company closure (2)
Compensation (576)
Complete response letters (25)
COVID-19 (2663)
CRISPR (47)
C-suite (258)
Cystic fibrosis (106)
Data (2353)
Decentralized trials (2)
Denatured (29)
Depression (47)
Diabetes (279)
Diagnostics (6467)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (117)
Drug shortages (28)
Duchenne muscular dystrophy (97)
Earnings (88771)
Editorial (41)
Employer branding (21)
Employer resources (149)
Events (115554)
Executive appointments (758)
FDA (17990)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (782)
Gene editing (116)
Generative AI (22)
Gene therapy (331)
GLP-1 (760)
Government (4554)
Grass and pollen (5)
Guidances (162)
Healthcare (19004)
Huntington's disease (25)
IgA nephropathy (29)
Immunology and inflammation (135)
Indications (30)
Infectious disease (2809)
Inflammatory bowel disease (147)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (100)
Interviews (323)
IPO (16804)
IRA (47)
Job creations (4060)
Job search strategy (1492)
Kidney cancer (10)
Labor market (43)
Layoffs (499)
Leadership (18)
Legal (8380)
Liver cancer (77)
Lung cancer (327)
Lymphoma (159)
Machine learning (9)
Management (59)
Manufacturing (344)
MASH (79)
Medical device (13470)
Medtech (13475)
Mergers & acquisitions (20399)
Metabolic disorders (731)
Multiple sclerosis (83)
NASH (17)
Neurodegenerative disease (99)
Neuropsychiatric disorders (29)
Neuroscience (1983)
NextGen: Class of 2025 (6637)
Non-profit (4528)
Now hiring (40)
Obesity (386)
Opinion (230)
Ovarian cancer (82)
Pain (103)
Pancreatic cancer (89)
Parkinson's disease (156)
Partnered (22)
Patents (251)
Patient recruitment (117)
Peanut (49)
People (59331)
Pharmaceutical (91)
Pharmacy benefit managers (20)
Phase I (20987)
Phase II (29769)
Phase III (22299)
Pipeline (1399)
Policy (160)
Postmarket research (2654)
Preclinical (8947)
Press Release (68)
Prostate cancer (109)
Psychedelics (31)
Radiopharmaceuticals (252)
Rare diseases (404)
Real estate (6258)
Recruiting (67)
Regulatory (23195)
Reports (47)
Research institute (2370)
Resumes & cover letters (358)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (80)
Series A (134)
Series B (91)
Service/supplier (12)
Sickle cell disease (55)
Special edition (17)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3730)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (55)
The Weekly (50)
Vaccines (720)
Venture capitalists (42)
Weight loss (256)
Women's health (36)
Worklife (16)
Date
Today (176)
Last 7 days (956)
Last 30 days (3235)
Last 365 days (33006)
2025 (12127)
2024 (35771)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54791)
2019 (47399)
2018 (35770)
2017 (33137)
2016 (32663)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Alabama (54)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (40773)
Australia (6530)
California (6461)
Canada (2080)
China (556)
Colorado (277)
Connecticut (282)
Delaware (161)
Europe (87133)
Florida (961)
Georgia (215)
Idaho (57)
Illinois (561)
India (26)
Indiana (332)
Iowa (11)
Japan (176)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (931)
Massachusetts (4842)
Michigan (228)
Minnesota (406)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1816)
New Mexico (29)
New York (1819)
North Carolina (1011)
North Dakota (8)
Northern California (2848)
Ohio (210)
Oklahoma (14)
Oregon (39)
Pennsylvania (1440)
Puerto Rico (13)
Rhode Island (33)
South America (1163)
South Carolina (26)
South Dakota (1)
Southern California (2424)
Tennessee (106)
Texas (961)
United States (24306)
Utah (190)
Virginia (160)
Washington D.C. (64)
Washington State (575)
West Virginia (3)
Wisconsin (59)
719,793 Results for "rigel pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
Rigel Pharmaceuticals, Inc. (“Rigel”) (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO®.
June 24, 2024
·
10 min read
Press Releases
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025
·
15 min read
Press Releases
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update
April 30, 2025
·
1 min read
Business
Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients
Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces a contractual partnership with Rigel Pharmaceuticals, Inc., effective July 1, 2024, bringing its comprehensive suite of services to support patients using GAVRETO® (pralsetinib).
June 27, 2024
·
8 min read
Press Releases
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors
March 10, 2025
·
2 min read
Deals
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
Rigel Pharmaceuticals, Inc. (“Rigel”) (Nasdaq: RIGL) today announced that it has entered into a definitive agreement to acquire the U.S. rights to GAVRETO® (pralsetinib) from Blueprint Medicines Corporation (“Blueprint”).
February 22, 2024
·
12 min read
Biotech Bay
Rigel Announces Reverse Stock Split - June 25, 2024
Rigel Pharmaceuticals, Inc. announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, effective at 12:01 a.m. Eastern Time on Thursday, June 27, 2024.
June 25, 2024
·
5 min read
Biotech Bay
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
Rigel Pharmaceuticals, Inc. announced one oral and four poster presentations at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain being held June 13-16, 2024, and online.
June 14, 2024
·
16 min read
Biotech Bay
Rigel to Present at the Jefferies Global Healthcare Conference
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company’s president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:30 am ET in New York, NY.
May 30, 2024
·
1 min read
Business
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Rigel Pharmaceuticals, Inc. announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer.
March 12, 2024
·
5 min read
1 of 71,980
Next
